

CORRECTION

Open Access



Corrections to: Checkpoint inhibitor therapy for cancer in solid organ transplantation recipients: an institutional experience and a systematic review of the literature

Noha Abdel-Wahab^{1,2}, Houssein Safa³, Ala Abudayyeh⁴, Daniel H. Johnson³, Van Anh Trinh³, Chrystia M. Zobniw³, Heather Lin⁵, Michael K. Wong³, Maen Abdelrahim⁶, A. Osama Gaber⁶, Maria E. Suarez-Almazor^{1†} and Adi Diab^{3*†}

Correction to: J Immunother Cancer (2019) 7:106
<https://doi.org/10.1186/s40425-019-0585-1>

Following publication of the original article [1], the authors reported an error in the Acknowledgments section. It should be read: ‘We are grateful to Mohsin Shah from the Department of Emergency Medicine at The University of Texas MD Anderson Cancer Center for assisting in study selection, and to Gregory F. Pratt from the Research Medical Library and Erica Goodoff, from the Department of Scientific Publications at The University of Texas MD Anderson Cancer Center for their valuable contributions.

Author details

¹Section of Rheumatology and Clinical Immunology, Department of General Internal Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA. ²Department of Rheumatology and Rehabilitation, Faculty of Medicine, Assiut University Hospitals, Assiut, Egypt. ³Department of Melanoma Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA. ⁴Section of Nephrology, Division of Internal Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA. ⁵Department of Biostatistics, The University of Texas MD Anderson Cancer Center, Houston, TX, USA. ⁶Houston Methodist Hospital, Houston, TX, USA.

Received: 14 June 2019 Accepted: 14 June 2019

Published online: 24 June 2019

Reference

1. Abdel-Wahab N, et al. Checkpoint inhibitor therapy for cancer in solid organ transplantation recipients: an institutional experience and a systematic review of the literature. *J Immunother Cancer*. 2019;7:106. <https://doi.org/10.1186/s40425-019-0585-1>.

* Correspondence: adiab@mdanderson.org

[†]Maria E. Suarez-Almazor and Adi Diab contributed equally to this work.

³Department of Melanoma Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA

Full list of author information is available at the end of the article

